VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | Genitourinary cancer highlights at ESMO 2022

Enrique Grande, MD, PhD, MSc, MD Anderson Cancer Center Madrid, Madrid, Spain, provides an overview of his highlights presented at the European Society for Medical Oncology (ESMO) 2022 Congress in the field of genitourinary cancer, including updates in PD-L1 testing and adjuvant therapy in urothelial cancer. Dr Grande additionally comments on the Phase III PIVOT-09 trial (NCT03729245) of nivolumab and an interleukin-2 prodrug, which was inferior to the investigator’s choice of treatment. This interview took place at the ESMO 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter